Skip to main content
Celyad Oncology SA logo

Celyad Oncology SA — Investor Relations & Filings

Ticker · CYAD ISIN · BE0974260896 LEI · 549300ORR0M8XF56OI64 BR Professional, scientific and technical activities
Open in API
Filings indexed 923 across all filing types
Latest filing 2025-08-05 AGM Information
Country BE Belgium
Listing BR CYAD

About Celyad Oncology SA

https://celyad.com/

Celyad Oncology is a biotechnology company primarily focused on unlocking the potential of its intellectual property in the field of cell therapy. The company discovers and develops innovative technologies for Chimeric Antigen Receptor T-cell (CAR-T) therapies aimed at treating cancer. Its differentiated strategy includes the advancement of proprietary technology platforms and CAR T-cell candidates designed to broaden the range of treatable cancer indications and overcome the main limitations of existing CAR T-cell therapies.

Recent filings

Filing Released Lang Actions
PV Notaire.5août2025.signed.pdf
AGM Information Classification · 100% confidence The document is a formal minutes record of a Board of Directors meeting for 'Celyad Oncology'. It details specific corporate governance procedures, including conflict of interest declarations under Belgian law (Code des sociétés et des associations), and resolutions regarding a capital increase (share issuance) with the suppression of preferential rights. While it discusses capital, it is primarily a record of board proceedings and governance decisions rather than a standalone financial report or a simple announcement. Given the nature of the document as a formal board meeting record detailing governance and capital structure decisions, it fits best under 'Regulatory Filings' as a catch-all for formal corporate legal/governance records that do not fit into specific categories like '10-K' or 'ER'.
2025-08-05 French
CELYAD_ Rapport de Commissaire - Augm de K 1 MEUR_VDEF_SIGNED_280725.pdf
Audit Report / Information Classification · 100% confidence The document is a formal 'Rapport d'évaluation' (Evaluation Report) issued by an auditor (BDO) regarding financial and accounting data presented by the Board of Directors of Celyad Oncology SA. It specifically relates to a capital increase (émission d'actions nouvelles) and the suppression of preferential subscription rights under Belgian company law (CSA). This is a standalone audit-related report concerning a specific corporate action, which fits the definition of an Audit Report/Information (AR) as it provides an independent assessment of financial data in a regulatory context, distinct from a full annual report or a simple announcement. FY 2025
2025-08-05 French
FR_Celyad_Rapport Special du CA_PIPE2025_23juillet2025.FE.pdf
Share Issue/Capital Change Classification · 100% confidence The document is a formal 'Rapport du Conseil d'Administration' (Board of Directors' Report) concerning a capital increase through the issuance of new shares, specifically detailing the suppression of subscription rights for existing shareholders in favor of a specific investor (Fortress). It cites specific articles of the Belgian Code of Companies and Associations (CSA) and provides a detailed justification for the capital increase, the subscription price, and the impact on shareholders. This is a primary corporate governance document related to capital structure changes and financing, fitting the 'Capital/Financing Update' category.
2025-08-05 French
20250724_CYAD-PR-PIPE-ENG.2.pdf
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a private placement financing (capital increase) by Celyad Oncology. It details the subscription agreement, the number of shares issued, the price per share, and the impact on the company's capital structure and cash runway. This fits the definition of a 'Capital/Financing Update' (CAP) as it describes specific fundraising activities and changes to the company's capital structure.
2025-08-05 English
20250724_CYAD-PR-PIPE-FR.2.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release from Celyad Oncology announcing a private placement of shares (capital increase) to Fortress Investment Group. It details the terms of the share issuance, the impact on capital structure, and the strategic rationale for the financing. This falls under the category of capital and financing updates, specifically involving the issuance of new shares.
2025-08-05 French
CELYAD - AGM & EGM May 2025 - Convening notice ENG.Final.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Convening Letter' for an Ordinary and Extraordinary General Meeting of Shareholders. It outlines the agenda items, voting procedures, quorum requirements, and participation instructions for the upcoming meeting on 20 May 2025. This type of document is sent to shareholders to provide information and request their participation/votes for the meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2025-04-18 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.